Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis

doi:10.7150/jca.15258

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/31038

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31038

Title:	Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis
Authors:	Liao, Kuang-Ming Chao, Tung-Bo Tian, Yu-Feng Lin, Ching-Yih Lee, Sung-Wei Chuang, Hua-Ying Chan, Ti-Chun Chen, Tzu-Ju Hsing, Chung-Hsi Sheu, Ming-Jen Li, Chien-Feng
Contributors:	Chi Mei Med Ctr, Dept Internal Med Yuans Gen Hosp, Dept Colorectal Surg Meiho Univ, Dept Hlth Business Adm Chi Mei Med Ctr, Div Gen Surg Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Chi Mei Med Ctr, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management Chi Mei Med Ctr, Dept Radiat Oncol Chi Mei Med Ctr, Dept Pathol Chi Mei Med Ctr, Dept Anesthesiol Natl Hlth Res Inst, Natl Inst Canc Res Southern Taiwan Univ Sci & Technol, Dept Biotechnol
Keywords:	PSAT1 Nasopharyngeal carcinoma prognosis trials
Date:	2016
Issue Date:	2018-01-18 11:40:22 (UTC+8)
Publisher:	Ivyspring Int Publ
Abstract:	Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR=2.856, 95% CI 1.599 to 5.101), DMFS (HR=3.305, 95% CI 1.720 to 6.347), LRFS (HR=2.834, 95% CI 1.376 to 5.835), and OS HR=2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.
Relation:	Journal of Cancer, v.7 n.9, pp.1088-1094
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
31038.pdf		742Kb	Adobe PDF	209	View/Open
index.html		0Kb	HTML	1158	View/Open

Loading...